Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Mohamed A. Kharfan-Dabaja, MD, Rami S. Komrokji, MD, Qing Zhang, PhD, David Sallman, MD, Asmita Mishra, MD, Najla H. Al Ali, BDS, MSc, Taiga Nishihori, MD, Teresa Field, MD, PhD, Karma Z Salem, MD, Janelle Perkins, PharmD, Ling Zhang, MD, Lynn C. Moscinski, MD, Hugo F. Fernandez, MD, Jeffrey E Lancet, MD, Alan F. List, MD, Claudio Anasetti, MD, Eric Padron, MD

Blood (2015) 126 (23): 4382.

https://doi.org/10.1182/blood.V126.23.4382.4382

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Kendra L Sweet, MD MS, Jeffrey E Lancet, MD, Ryan Hillgruber, BS, Megan Melody, MS, Amina Llishi, Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Teresa Field, MD, PhD

Blood (2015) 126 (23): 4388.

https://doi.org/10.1182/blood.V126.23.4388.4388

Published: 2015

Journal Articles

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Michael T Tees, MD MPH, Brian C Betts, MD, Hugo F Fernandez, MD, Ryan Hillgruber, Ernesto Ayala, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD, Marcie L Riches, MD MS

Blood (2014) 124 (21): 2475.

https://doi.org/10.1182/blood.V124.21.2475.2475

Published: 2014

Journal Articles

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Chiara Frairia, MD, Jamie Shapiro, PharmD, Jongphil Kim, PhD, Joseph Pidala, MD PhD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2500.

https://doi.org/10.1182/blood.V124.21.2500.2500

Published: 2014

Journal Articles

Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease

Joseph Pidala, MD PhD, Jongphil Kim, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2502.

https://doi.org/10.1182/blood.V124.21.2502.2502

Published: 2014

Journal Articles

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Lia Perez, MD, Teresa Field, MD PhD, Marcie L Riches, MD MS, Hugo F Fernandez, MD, Frederick L Locke, MD, Brian C Betts, MD, Joseph Pidala, MD PhD, Erika Elmer, CCRP, Francisca Beato, BS, Maritza Lienlaf, MS, Pedro Horna, MD, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2014) 124 (21): 1167.

https://doi.org/10.1182/blood.V124.21.1167.1167

Published: 2014

Journal Articles

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Maria Gabriela Corrales-Yepez, MD, Teresa Field, MD, PhD, Alan List, MD, Claudio Anasetti, MD, Janelle Perkins, PharmD, Najla H Al Ali, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Mohamed A. Kharfan-Dabaja, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 5222.

https://doi.org/10.1182/blood.V122.21.5222.5222

Published: 2013

Journal Articles

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Ryan Hillgruber, Taiga Nishihori, MD, Asmita Mishra, MD, Joseph Pidala, MD, MS, Ernesto Ayala, MD, Frederick L Locke, MD, Melissa Alsina, MD, Brian C. Betts, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Alan List, MD, Rami S Komrokji, MD, Mohamed A. Kharfan-Dabaja, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2152.

https://doi.org/10.1182/blood.V122.21.2152.2152

Published: 2013

Journal Articles

A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease

Lia Perez, MD, Hugo F Fernandez, MD, Marcie Tomblyn, MD, MS, Frederick L Locke, MD, Teresa Field, MD, PhD, Joseph Pidala, MD, MS, Erika Elmer, CCRP, Francisca Beato, BS, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2013) 122 (21): 3308.

https://doi.org/10.1182/blood.V122.21.3308.3308

Published: 2013

Journal Articles

Survival Advantage of Cell Therapy Over Cytotoxic Therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem Cell Transplantation

Ghada M Kunter, MD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Frederick L Locke, MD, Teresa Field, MD, PhD, Hugo F Fernandez, MD

Blood (2012) 120 (21): 1994.

https://doi.org/10.1182/blood.V120.21.1994.1994

Published: 2012

Journal Articles

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Joseph Pidala, MD, MS, Jongphil Kim, PhD, Heather Jim, PhD, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed A Kharfan-Dabaja, MD, Brian C. Betts, MD, Taiga Nishihori, MD, Mian Xu, William E. Janssen, PhD, Frederick L Locke, MD, Ernesto Ayala, MD, Lia Perez, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Leonel Ochoa, Melissa Alsina, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 323.

https://doi.org/10.1182/blood.V118.21.323.323

Published: 2011

Journal Articles

Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission

Ghada M Kunter, MD, Janelle Perkins, PharmD, Lia Perez, MD, Joseph Pidala, MD, MS, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS, Hugo F. Fernandez, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 891.

https://doi.org/10.1182/blood.V118.21.891.891

Published: 2011

Journal Articles

Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

Rami S. Komrokji, MD, Najla H Al Ali, M.S, E Alrawi, MD, Eric Padron, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jeffrey E. Lancet, MD, Alan F. List, MD

Blood (2011) 118 (21): 1712.

https://doi.org/10.1182/blood.V118.21.1712.1712

Published: 2011

Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 3022.

https://doi.org/10.1182/blood.V118.21.3022.3022

Published: 2011

Journal Articles

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jongphil Kim, PhD, Hugo F. Fernandez, MD, Lia Perez, MD, Ernesto Ayala, MD, Mohamed Kharfan-Dabaja, MD, Marcie Tomblyn, MD, MS, Daniel Sullivan, MD, Claudio Anasetti, MD

Blood (2010) 116 (21): 3499.

https://doi.org/10.1182/blood.V116.21.3499.3499

Published: 2010

Journal Articles

Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes

Maria Corrales-Yepez, Jeffrey E. Lancet, MD, Alan F. List, MD, Mohamed A. Kharfan-Dabaja, MD, Teresa Field, MD, PhD, Eric Padron, MD, Rami S. Komrokji, MD

Blood (2010) 116 (21): 444.

https://doi.org/10.1182/blood.V116.21.444.444

Published: 2010

Journal Articles

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Jongphil Kim, Ernesto Ayala, MD, Melissa Alsina, MD, Jose-Leonel ochoa-Bayona, M.D., Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 1333.

https://doi.org/10.1182/blood.V116.21.1333.1333

Published: 2010

Journal Articles

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jose-Leonel ochoa-Bayona, M.D., Melissa Alsina, MD, Ernesto Ayala, MD, Jongphil Kim, Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 2381.

https://doi.org/10.1182/blood.V116.21.2381.2381

Published: 2010

Journal Articles

Plasmablastic Lymphoma: A Series of 16 Cases with the Largest Collection of 9 HIV-Negative Cases

Jijun Liu, MD, Ling Zhang, MD, Ernesto Ayala, MD, Teresa Field, MD, PhD, Jose L. Ochoa-Bayona, MD, Lia Perez, MD, Celeste M. Bello, MD, Paul A. Chervenick, MD, Salvador Bruno, MD, Eduardo M. Sotomayor, MD, Lubomir Sokol, MD, PhD

Blood (2010) 116 (21): 4162.

https://doi.org/10.1182/blood.V116.21.4162.4162

Published: 2010

Journal Articles

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Joseph A. Pidala, MD, Daanish Hoda, Norma Salgado-Vila, Jongphil Kim, PhD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Teresa Field, MD, PhD, Lia Perez, MD, Ernesto Ayala, MD, J. Leonel Ochoa-Bayona, Jyotishankar Raychaudhuri, Melissa Alsina, MD, John N Greene, MD, William E. Janssen, PhD, Hugo F. Fernandez, MD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD

Blood (2009) 114 (22): 2235.

https://doi.org/10.1182/blood.V114.22.2235.2235

Published: 2009

NARROW

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission

Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat (LBH589) in Addition to Glucocorticoids in Patients with Acute Graft-Versus-Host Disease

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease

Survival Advantage of Cell Therapy Over Cytotoxic Therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem Cell Transplantation

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission

Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Plasmablastic Lymphoma: A Series of 16 Cases with the Largest Collection of 9 HIV-Negative Cases

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only